HC Wainwright Has Optimistic Outlook of ATRA Q2 Earnings

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) – HC Wainwright boosted their Q2 2025 EPS estimates for shares of Atara Biotherapeutics in a report released on Tuesday, January 28th. HC Wainwright analyst R. Burns now expects that the biotechnology company will post earnings of ($4.04) per share for the quarter, up from their prior forecast of ($4.15). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Atara Biotherapeutics’ current full-year earnings is ($9.86) per share. HC Wainwright also issued estimates for Atara Biotherapeutics’ Q4 2025 earnings at ($3.59) EPS and FY2025 earnings at ($8.41) EPS.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, beating the consensus estimate of ($3.77) by $0.84. The firm had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same quarter last year, the company earned ($16.50) EPS.

Several other research firms also recently commented on ATRA. TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. Canaccord Genuity Group cut their target price on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, January 17th. RODMAN&RENSHAW cut Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 21st. Finally, Rodman & Renshaw assumed coverage on Atara Biotherapeutics in a research note on Friday, December 20th. They issued a “buy” rating and a $25.00 price objective on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.75.

Atara Biotherapeutics Stock Performance

Shares of NASDAQ:ATRA opened at $8.09 on Thursday. The company has a market capitalization of $46.60 million, a PE ratio of -0.31 and a beta of 0.51. The stock has a fifty day moving average of $11.78 and a 200-day moving average of $9.93. Atara Biotherapeutics has a one year low of $5.40 and a one year high of $39.50.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ATRA. Geode Capital Management LLC grew its position in Atara Biotherapeutics by 9.5% in the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 4,043 shares in the last quarter. State Street Corp increased its holdings in Atara Biotherapeutics by 52.3% during the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after buying an additional 7,680 shares during the last quarter. Vestal Point Capital LP raised its position in Atara Biotherapeutics by 11.3% during the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after acquiring an additional 12,677 shares in the last quarter. FMR LLC lifted its stake in Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 7,381 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Atara Biotherapeutics in the 2nd quarter valued at about $79,000. 70.90% of the stock is currently owned by institutional investors and hedge funds.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.